Moberg Pharma Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
5
- Stock Symbol
-
MOB
- Investments
-
10
- Share Price
-
$1.06
- (As of Friday Closing)
Moberg Pharma General Information
Description
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
Contact Information
Website
www.mobergpharma.seCorporate Office
- Gustavslundsvägen 50, 5th floor
- 167 51 Bromma
- Sweden
Corporate Office
- Gustavslundsvägen 50, 5th floor
- 167 51 Bromma
- Sweden
Moberg Pharma Stock Performance
As of 13-Nov-2026, Moberg Pharma’s stock price is $1.06. Its current market cap is $50.2M with 47.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.06 | $1.04 | $0.85 - $1.52 | $50.2M | 47.2M | 65.6K | -$0.04 |
Moberg Pharma Financials Summary
As of 30-Sep-2026, Moberg Pharma has a trailing 12-month revenue of $1.97M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 32,256 | 27,156 | 15,407 | 32,751 |
| Revenue | 1,972 | 1,378 | 928 | 0 |
| EBITDA | (1,660) | (2,617) | (2,223) | (2,386) |
| Net Income | (2,026) | (2,772) | (24,122) | (1,984) |
| Total Assets | 67,851 | 74,144 | 63,995 | 63,512 |
| Total Debt | 130 | 277 | 375 | 474 |
Moberg Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Moberg Pharma Comparisons
Industry
Financing
Details
Moberg Pharma Competitors (18)
One of Moberg Pharma’s 18 competitors is Orexo, a Formerly VC-backed company based in Uppsala, Sweden.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orexo | Formerly VC-backed | Uppsala, Sweden | ||||
| axicorp | Corporate Backed or Acquired | Friedrichsdorf, Germany | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Indivior | Corporate Backed or Acquired | North Chesterfield, VA |
Moberg Pharma Patents
Moberg Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260102363-A1 | Treatment method and antifungal composition | Active | 08-Dec-2020 | ||
| AU-2021396584-A1 | Treatment regimen for onchyomycosis using allylamine antifungal compositions | Inactive | 08-Dec-2020 | ||
| AU-2021396584-A9 | Treatment regimen for onchyomycosis using allylamine antifungal compositions | Inactive | 08-Dec-2020 | ||
| CA-3201760-A1 | Treatment regimen for onchyomycosis using allylamine antifungal compositions | Pending | 08-Dec-2020 | ||
| EP-4259116-A1 | Treatment regimen for onchyomycosis using allylamine antifungal compositions | Pending | 08-Dec-2020 | A61K47/12 |
Moberg Pharma Signals
Moberg Pharma Investments & Acquisitions (10)
Moberg Pharma’s most recent deal was a Corporate with Allderma. The deal was made on 08-Nov-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Allderma | 08-Nov-2023 | Corporate | Pharmaceuticals | ||
| Prestige Consumer Healthcare (Dermoplast Pain Relieving Spray) | 31-Dec-2016 | Corporate Asset Purchase | Buildings and Property | ||
| New Skin | 08-Jul-2016 | Merger/Acquisition | Buildings and Property | ||
| Prestige Brands (New Skin, Fiber Choice, PediaCare) | 08-Jul-2016 | Corporate Asset Purchase | Buildings and Property | ||
| Fiber Choice | 30-Jun-2016 | Merger/Acquisition | Food Products |
Moberg Pharma ESG
Risk Overview
Risk Rating
Updated July, 31, 2023
33.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Pharmaceuticals
Subindustry
of 435
Rank
Percentile
Moberg Pharma Exits (3)
Moberg Pharma’s most recent exit was on 08-Nov-2023 from Allderma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Allderma | 08-Nov-2023 | Completed |
|
||
| Fiber Choice | 30-Jun-2016 | Completed |
|
||
| Moberg Pharma (Balmex) | 24-Apr-2015 | Corporate Asset Purchase | Completed |
Moberg Pharma FAQs
-
When was Moberg Pharma founded?
Moberg Pharma was founded in 2006.
-
Where is Moberg Pharma headquartered?
Moberg Pharma is headquartered in Bromma, Sweden.
-
What is the size of Moberg Pharma?
Moberg Pharma has 5 total employees.
-
What industry is Moberg Pharma in?
Moberg Pharma’s primary industry is Pharmaceuticals.
-
Is Moberg Pharma a private or public company?
Moberg Pharma is a Public company.
-
What is Moberg Pharma’s stock symbol?
The ticker symbol for Moberg Pharma is MOB.
-
What is the current stock price of Moberg Pharma?
As of 13-Nov-2026 the stock price of Moberg Pharma is $1.06.
-
What is the current market cap of Moberg Pharma?
The current market capitalization of Moberg Pharma is $50.2M.
-
What is Moberg Pharma’s current revenue?
The trailing twelve month revenue for Moberg Pharma is $1.97M.
-
Who are Moberg Pharma’s competitors?
Orexo, axicorp, Novartis, Pfizer (Vienna), and Indivior are some of the 18 competitors of Moberg Pharma.
-
What is Moberg Pharma’s annual earnings per share (EPS)?
Moberg Pharma’s EPS for 12 months was -$0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process